SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the U.S. Department of Commerce utilizes it for on-chain economic data verification and distribution, sparking excitement about real-world asset (RWA) integration. The community is discussing its potential to disrupt the finance industry and outperform competitors, drawing comparisons to Chainlink and CRO. Some traders are noting technical indicators that suggest potential for further gains.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amid mixed sentiment, with some community members highlighting its infrastructure role and potential for developers, while others express frustration with its price performance and call it a "scam token." Discussions also revolve around the upcoming Neura L1 blockchain and its potential impact on the token's utility and value, with some hoping for a coin burn mechanism to drive demand.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to concerns about production timelines for their Gravity SUV and the overall company's profitability, reflected in negative sentiment from some investors. Despite a recent commercial spot during an NFL game and news of accelerated Gravity SUV production, some community members express skepticism about Lucid's financial future and the effectiveness of the reverse stock split. Discussions also involve potential future funding from Saudi PIF and comparisons to other EV manufacturers like Tesla and Rivian.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending amid community discussions around a potential breakout and anticipation for news related to its partnership with Nvidia ($NVDA). Some traders speculate about a possible acquisition, while others are focused on insider trading activity and the impact of the new CEO, Chris Allexandre, on the company's future direction in AI data centers.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

Trump For President

TRUMP.X is trending as the crypto market reacts to speculation around Trump's political activities and potential influence on the coin's value. The community is actively discussing price predictions and potential pumps, while also debating the merits and risks associated with investing in meme coins linked to public figures. Broader market factors, including economic data and potential policy changes, are also being considered in relation to the token's future performance.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending due to recent financial guidance updates and the completed acquisition of Melinta Therapeutics, with the community actively discussing the potential impacts of the acquisition and future revenue projections. Some are concerned about potential executive stock sales, while others are optimistic about the company's growth and the potential for a short squeeze. Discussions also revolve around DefenCath's adoption rates and potential CMS policy changes.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as investors discuss its aggressive capital allocation strategy amid strong gold prices, including a massive buyback program and significant shareholder returns. Community members are weighing the impact of these factors, alongside potential cost-cutting measures and unusual options activity, on the company's future performance and stock price, with some highlighting its potential for further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?

What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's  What You Should Know

Oric Pharmaceuticals' stock hit its highest levels in three months on Thursday after the company unveiled promising preliminary results from its Phase 1b trial of ORIC-944, an AR inhibitor for metastatic castration-resistant prostate cancer (mCRPC).Shares of the pharma company soared 33.5% to close at $7.97 on Thursday.&nbsp;The company said that the trial showed potentially strong performance in both efficacy and safety, as 59% of patients reached a PSA50 response rate.&nbsp;This means that over half of the study participants saw an over 50% reduction in prostate-specific antigen (PSA) levels.Nearly all of these PSA responses were confirmed, and 24% of patients achieved PSA90 responses, indicating a 90% drop in PSA levels.The drug was tested with two established AR inhibitors — apalutamide (Erleada) and darolutamide (Nubeqa) — and PSA responses were consistent across all doses and both combinations.&nbsp;Most patients remained on therapy, with several approaching or surpassing one year of treatment duration.The safety profile was favorable because most adverse events were categorized as Grade 1 or 2.&nbsp;A single Grade 3 diarrhea event occurred, while no Grade 4 or 5 treatment-related events were linked to the medication.Meanwhile, ORIC also announced a $125 million private placement, which it said would extend its cash runway into the second half of 2027, covering the expected readout of its first global Phase 3 trial in 1H 2026.The initiation of ORIC's global registrational Phase 3 trial for ORIC-944 is planned for the first half of 2026.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 194% surge in 24-hour message volume.One user expressed optimism about the stock soon reaching $10 again.&nbsp;<stembedurl>https://stocktwits.com/OK78/message/616104324</stembedurl>However, another user questioned the private placement, suggesting it might be a setup for short sellers.They cited concerns over the company’s recent $125 million PIPE financing last year, which was initially expected to last through late 2026.&nbsp;“So, in the period of 12 months, they've diluted the stock with $250 million of new shares.”<stembedurl>https://stocktwits.com/Any_Day_Now/message/616156552</stembedurl>The stock has declined 3.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial

The company also announced a $125 million private placement to fund its upcoming Phase 3 trial for ORIC-944 in metastatic prostate cancer.

Equity

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year PR Newswire VANCOUVER, BC, Jan. 15, 2025 Issued on behalf...

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration PR Newswire SAN FRANCISCO, Sept. 17...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.39	--	--	N/A
Q2 '25	-$0.44	-$0.47	-6.09%	MISSED
Q1 '25	-$0.51	-$0.42	17.83%	BEAT
Q4 '24	-$0.50	-$0.51	-1.37%	MISSED
Q3 '24	-$0.48	-$0.49	-2.47%	MISSED

ORIC
ORIC Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest ORIC News

ORIC ORIC Pharmaceuticals Inc